REGENXBIO Inc. has announced positive interim data from its Phase I/II AFFINITY DUCHENNE trial involving RGX-202, a potential gene therapy for Duchenne muscular dystrophy. The trial results indicate consistent functional, safety, and biomarker benefits, with participants in dose level 2 surpassing external natural history controls on key functional measures. Biomarker data showed robust microdystrophin expression, with one participant achieving 118.6% expression compared to controls. The trial, which aims to enroll around 30 patients in the U.S. and Canada by 2025, supports a potential Biologics License Application submission using the accelerated approval pathway in mid-2026. REGENXBIO plans to release top-line data in the first half of 2026. A webcast discussing these developments is scheduled for 8:00 a.m. EST, accessible via the company's website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。